Back to top

crispr: Archive

Zacks Equity Research

CRISPR Therapeutics (CRSP) Q3 Loss Narrower Than Expected

CRISPR Therapeutics (CRSP) beats the mark for earnings and misses the same for sales in the third quarter.

ALKSPositive Net Change VRTXPositive Net Change ACADPositive Net Change CRSPPositive Net Change

Zacks Equity Research

Vertex (VRTX) Q3 Earnings Beat, Sales Miss, Raises '23 View

Vertex's (VRTX) third-quarter results reflect a year-over-year increase in revenues. The company raises its net product sales guidance for 2023.

VRTXPositive Net Change CRSPPositive Net Change APLSPositive Net Change ANIXNo Net Change

Zacks Equity Research

CRISPR (CRSP) to Report Q3 Earnings: What's in the Cards?

Devoid of marketed drugs, investors will focus on CRISPR Therapeutics' (CRSP) pipeline, specifically regulatory updates on lead candidate exa-cel.

GSKPositive Net Change BIIBPositive Net Change VRTXPositive Net Change CRSPPositive Net Change